Swiss Timing Is Spot-On For EU Medtech Reg Integration
Executive Summary
Switzerland, outside the EU and the European Economic Area, has been efficient in preparing to work under the new EU medtech regulations. It’s a hoped-for model for UK stakeholders as Brexit trade talks approach.
You may also be interested in...
Exec: EU May Lose Out On More Innovation As MDR Pressure On NBs Begins To Bite
The new MDR and IVDR were drafted with highest interests of EU patients in mind, but they may yet have a devastating effect on the EU's speedy access to innovation in general, and on medtech SMEs in particular. That is the view of one Swiss medtech CEO; he also has grave concerns about the loss of EU notified bodies and the impact on manufacturers.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.